Glaucoma therapy developer Eyenovia sets terms for $30 million IPO
Eyenovia, which is developing micro-formulations of common eye therapies, announced terms for its IPO on Tuesday.
The New York, NY-based company plans to raise $30 million by offering 2.7 million shares at a price range of $10 to $12. Insiders intend to purchase $5 million worth of shares in the offering. At the midpoint of the proposed range, Eyenovia would command a fully diluted market value of $125 million.
Eyenovia was founded in 2014 and plans to list on the Nasdaq under the symbol EYEN. Ladenburg Thalmann and Roth Capital are the joint bookrunners on the deal. It is expected to price during the week of January 22, 2018.
The article Glaucoma therapy developer Eyenovia sets terms for $30 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.